Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

William Blair analyst Andy Hsieh noted on Monday that Viking’s results surpassed Wall Street expectations and outperformed ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt in the third quarter, a potential relief for ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Pfizer (PFE) offered up some more details on its weight loss drug pipeline on Tuesday during a call with investors after it ...